About Probable G-protein coupled receptor 33
Probable G-protein coupled receptor 33 (GPR33) is a protein
from Homo sapiens identified by UniProt accession
Q49SQ1, 333 residues long.
MolForge cross-references it against 0 known binders and
11 disease associations.
Target properties
| Protein name | Probable G-protein coupled receptor 33 |
| UniProt accession | Q49SQ1 |
| Gene | GPR33 |
| Organism | Homo sapiens |
| Length | 333 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (11)
Diseases linked to this target (Open Targets).
- epidermolysis bullosa simplex with nail dystrophy · score 0.11
- Benign familial chorea · score 0.07
- lymphocyte count · score 0.07
- Ataxia - oculomotor apraxia type 1 · score 0.05
- early-onset generalized limb-onset dystonia · score 0.05
- Tourette syndrome · score 0.02
- obsessive-compulsive disorder · score 0.02
- neoplasm · score 0.00
- Nail dystrophy · score 0.00
- multiple epiphyseal dysplasia · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q49SQ1-F1 | alphafold | PREDICTED | 87.58 | — |
Amino-acid sequence (333 residues)
MDLINSTDYL INASTLVRNS TQFLAPASKM IIALSLYISS IIGTITNGLY LWVLRFKMKQ TVNTLLFFHL ILSYFISTMI LPFMATSQLQ DNHWNFGTAL CKVFNGTLSL GMFTSVFFLS AIGLDRYLLT LHPVWSQQHR TPRWASSIVL GVWISAAALS IPYLIFRETH HDRKGKVTCQ NNYAVSTNWE SKEMQASRQW IHVACFISRF LLGFLLPFFI IIFCYERVAS KVKERSLFKS SKPFKVMMTA IISFFVCWMP YHIHQGLLLT TNQSLLLELT LILTVLTTSF NTIFSPTLYL FVGENFKKVF KKSILALFES TFSEDSSVER TQT
Explore Probable G-protein coupled receptor 33 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets